These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8318682)

  • 1. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
    Powe NR; Griffiths RI; Watson AJ; Anderson GF; de Lissovoy G; Greer JW; Herbert RJ; Milam RA; Whelton PK
    J Am Soc Nephrol; 1994 Jan; 4(7):1455-65. PubMed ID: 8161727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    J Am Soc Nephrol; 1994 Apr; 4(10):1809-13. PubMed ID: 8068879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
    Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients.
    Ifudu O; Macey LJ; Friedman EA
    ASAIO J; 1995; 41(3):M426-30. PubMed ID: 8573839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconciling decision models with the real world. An application to anaemia of renal failure.
    Shih YC; Kauf TL
    Pharmacoeconomics; 1999 May; 15(5):481-93. PubMed ID: 10537965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.
    Moyneur E; Bookhart BK; Mody SH; Fournier AA; Mallett D; Duh MS
    Dis Manag; 2008 Feb; 11(1):49-58. PubMed ID: 18279115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.